SenzaGen, a Swedish non-animal testing company, reported a 13% year-over-year increase in second-quarter revenue to SEK 15.3 million. The company's VitroScreen subsidiary, which accounts for a significant portion of its revenue, saw a turnaround in the quarter, driven by increased order intake and the securing of two major orders.
The company's operating loss narrowed during the quarter, while earnings per share improved compared to the prior year period. First-half revenue reached SEK 30.20 million, with a loss per share of SEK 0.13.
VitroScreen's increased order intake contributed to the revenue growth, with the subsidiary securing two major orders that are expected to drive further growth in the coming months. SenzaGen maintained its gross margin at levels consistent with historical performance and reported positive operating cash flow, thanks to effective cost management.
The company attributes its growth to the European Union's roadmap to phase out animal testing, which is expected to strengthen long-term market demand for its non-animal testing solutions. SenzaGen's strategic initiatives and regulatory trends also support its path toward long-term profitable growth.
Revenue Growth Drives SenzaGen's Q2 Results
SenzaGen's Q2 revenue growth of 13% is a significant milestone for the company, driven by the turnaround at its VitroScreen subsidiary. The company's non-animal testing solutions are gaining traction in the market, and its strategic initiatives and regulatory trends support its path toward long-term profitable growth.
Order Intake Boosts VitroScreen's Revenue
VitroScreen's increased order intake contributed to the revenue growth in the quarter, with the subsidiary securing two major orders that are expected to drive further growth in the coming months. The company's effective cost management and positive operating cash flow also support its growth plans.
Long-term Growth Prospects
SenzaGen's growth prospects are driven by the European Union's roadmap to phase out animal testing, which is expected to strengthen long-term market demand for its non-animal testing solutions. The company's strategic initiatives and regulatory trends also support its path toward long-term profitable growth.
- ethereum
- markets
- defi-news
- regulation
- vitroscreen
- non-animal testing
- eu roadmap
- animal testing
- eu regulation
